logo
episode-header-image
Sep 2023
1h 19m

Downstream: Big Pharma’s Secrets w/ Nick...

Novara Media
About this episode
Nick Dearden has been an economic justice campaigner for over 20 years, and his attention was on the pharmaceutical industry when Covid-19 hit. But as the world began to sing the praises of pharmaceutical companies, Nick saw an unprecedented PR coup. Giant corporations capitalised on the crisis, tightening their stranglehold over the health of the […] 
Up next
Yesterday
Downstream: China Is Building While the West Crumbles w/ Dan Wang
Dan Wang is a technology analyst and author whose life experience, spent partly in North America, partly in China, sets him up as an authoritative observer of the differences and similarities between the American and Chinese empires. In conversation with Aaron Bastani, Wang share ... Show More
2h 1m
Aug 18
Downstream: A Reckoning Is Coming For The Establishment Over Gaza w/ Owen Jones
Owen Jones is a journalist and the author of ‘Chavs’, ‘The Establishment’, and ‘This Land’. He has spent the last 21 months relentlessly reporting and commenting on Israel’s genocidal war on Gaza. He joins Ash Sarkar to talk about how media bias actually works, the history of the ... Show More
1h 18m
Aug 11
Downstream: The Ancient Indian History Our Schools Don’t Teach w/ William Dalrymple
Ash Sarkar sat down at EartH Hackney with acclaimed historian and author William Dalrymple. Picking up where they left off last time they spoke on Downstream, Sarkar and Dalrymple had a wide-ranging conversation at the crossroads of empire, resistance, and the long shadows of col ... Show More
1h 5m
Recommended Episodes
Mar 2024
Long Reads: Big Pharma's Toxic Record w/ Nick Dearden
From the HIV/AIDS crisis, to the opioid epidemic, to the COVID-19 pandemic, pharmaceutical corporations have been accused of profiteering at the expense of countless lives. Nick Dearden, director of Global Justice Now and the author of a new book called Pharmanomics: How Big Phar ... Show More
53m 19s
Sep 2023
Will Big Pharma Ever Face Justice for the Opioid Crisis?
The Supreme Court recently blocked a bankruptcy deal that would have given full immunity to the members of the Sackler family who once controlled Purdue Pharma, the maker of OxyContin. Trevor Noah calls out the frustrating contradictions within the initial deal and shares his tho ... Show More
25m 31s
May 2024
This Is a Very Weird Moment in the History of Drug Laws
Drug policy feels very unsettled right now. The war on drugs was a failure. But so far, the war on the war on drugs hasn’t entirely been a success, either.Take Oregon. In 2020, it became the first state in the nation to decriminalize hard drugs. It was a paradigm shift — treating ... Show More
1h 2m
Sep 2015
Big Pharma: Conspiracies and Cover-ups
Big Pharma gets a bad name in the press, and the actions of multinational pharmaceutical companies are often the subject of various conspiracies - but are any of the allegations true? Learn more about theories behind political corruption, tainted medicine and more. Learn more abo ... Show More
57m 33s
Dec 2023
Opioid Victims Have a Settlement. Will the Supreme Court Undo It?
The opioid epidemic has been one of the biggest public health disasters in generations. The drug company at the heart of the crisis, Purdue Pharma, maker of the prescription painkiller OxyContin, agreed to a multibillion-dollar deal to settle thousands of claims against it — but ... Show More
23m 50s
Oct 2021
Sick Money (Pt 2): How Big Pharma made a killing from the pandemic
The second of two episodes this week, taking a deep dive into the pharmaceutical industry.Big drug companies have won plaudits for their work producing Covid vaccines within a year of the start of the pandemic. How much money are they making from them? And why are vaccines for ot ... Show More
24m 39s
Sep 2023
Why One Drug Company Held Back a Better Drug
For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.Rebecca Robbins, who co ... Show More
35m 38s